A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Cetrelimab (Primary) ; Erdafitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 07 Aug 2018 New source identified and integrated- Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI-184056)
- 05 Jul 2018 Planned number of patients changed from 49 to 30.